Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine potential modification of the relationship between paroxetine serum concentration (PSC) and serotonin transporter (SERT)-occupancy by single nucleotide polymorphisms (SNPs) of the ABCB1 gene, coding for the P-glycoprotein (P-gp) pump, in MDD patients.
|
31634334 |
2020 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to examine the effect of ABCB1 polymorphisms and the serum concentrations on the efficacy and tolerability of venlafaxine in patients with major depressive disorder (MDD).
|
28079463 |
2017 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms.
|
27309038 |
2016 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this meta-analysis, we systematically summarized 16 pharmacogenetic studies focused on the association of ABCB1 variants and antidepressant treatment outcome in patients with MD (overall n = 2695).
|
25847751 |
2015 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
The authors genotyped 10 ABCB1 single-nucleotide polymorphisms (SNPs) in 683 patients with major depressive disorder treated for at least 2 weeks, of whom 576 completed 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine (all substrates for P-glycoprotein) in a large randomized, prospective, pragmatic trial.
|
25815420 |
2015 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors genotyped 10 ABCB1 single-nucleotide polymorphisms (SNPs) in 683 patients with major depressive disorder treated for at least 2 weeks, of whom 576 completed 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine (all substrates for P-glycoprotein) in a large randomized, prospective, pragmatic trial.
|
25815420 |
2015 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggested that C3435T polymorphism in the ABCB1 gene may be an indicator of the susceptibility to major depression, without a likely treatment response to citalopram in a Turkish population.
|
24911075 |
2014 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Our results suggested that C3435T polymorphism in the ABCB1 gene may be an indicator of the susceptibility to major depression, without a likely treatment response to citalopram in a Turkish population.
|
24911075 |
2014 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Our results suggest that genetic variability of the ABCB1 is associated with MDD development in male Portuguese patients.
|
24200053 |
2014 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that genetic variability of the ABCB1 is associated with MDD development in male Portuguese patients.
|
24200053 |
2014 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In order to resolve these inconsistencies, we conducted a study in a large cohort of patients with major depressive disorder with the aim to unravel the association of ABCB1 variants with adverse effects of antidepressants and in particular with selective serotonin reuptake inhibitors (SSRIs), which display affinity as substrate for P-gp.
|
22641028 |
2013 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
In this study we investigated 36 single nucleotide polymorphisms within 10 genes previously associated with major depression and bipolar disorder, as well as with the response to their treatment (ABCB1, ABCB4, TAP2, CLOCK, CPLX1, CPLX2, SYN2, NRG1, 5HTR1A and GPRIN2).
|
23273899 |
2013 |
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
In order to resolve these inconsistencies, we conducted a study in a large cohort of patients with major depressive disorder with the aim to unravel the association of ABCB1 variants with adverse effects of antidepressants and in particular with selective serotonin reuptake inhibitors (SSRIs), which display affinity as substrate for P-gp.
|
22641028 |
2013 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
|
23188198 |
2012 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined whether functional polymorphisms of ABCB1 give susceptibility to major depressive disorder (MDD).
|
22306099 |
2012 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that single nucleotide polymorphisms in the ABCB1 gene may be indicators of the severity of depression and of the likely S-CIT treatment remission response in MDD.
|
20859246 |
2011 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.
|
17913323 |
2008 |
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results indicated that MDR1 variants G2677T and C3435T are not associated with therapeutic response to paroxetine in patients with major depressive disorder.
|
18550244 |
2008 |